FdaApplication
NDA 207946
Identifiers
- fda_app_no: NDA207946
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2015-05-18 |
Revenue by product
INVEGA TRINZA
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $1.0B |
| Q4 2025 | $986.0M |
| Q3 2025 | $929.0M |
| Q2 2025 | $992.0M |
| Q1 2025 | $903.0M |
| Q4 2024 | $1.1B |
| Q3 2024 | $1.0B |
| Q2 2024 | $1.1B |
| Q1 2024 | $1.1B |
| Q4 2023 | $1.0B |
| Q3 2023 | $1.0B |
| Q2 2023 | $1.0B |
| Q1 2023 | $1.0B |
| Q4 2022 | $1.0B |
| Q3 2022 | $1.0B |
| Q2 2022 | $1.1B |
| Q1 2022 | $1.0B |
| Q4 2021 | $1.0B |
| Q3 2021 | $1.0B |
| Q2 2021 | $1.0B |
| Q1 2021 | $965.0M |
| Q4 2020 | $965.0M |
| Q3 2020 | $926.0M |
| Q2 2020 | $879.0M |
| Q1 2020 | $883.0M |
| Q4 2019 | $871.0M |
| Q3 2019 | $851.0M |
| Q2 2019 | $818.0M |
| Q1 2019 | $790.0M |
| Q4 2018 | $763.0M |
| Q3 2018 | $749.0M |
| Q2 2018 | $720.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| INVEGA HAFYERA | PALIPERIDONE PALMITATE | 1.560GM/5ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA HAFYERA | PALIPERIDONE PALMITATE | 1.092GM/3.5ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA TRINZA | PALIPERIDONE PALMITATE | 546MG/1.75ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA TRINZA | PALIPERIDONE PALMITATE | 273MG/0.875ML (273MG/0.875ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA TRINZA | PALIPERIDONE PALMITATE | 410MG/1.315ML (311.79MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
| INVEGA TRINZA | PALIPERIDONE PALMITATE | 819MG/2.625ML (312MG/ML) | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR |
6 products